We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 06, 2020

Impact of Adjuvant Trastuzumab on Locoregional Failure Rates in a Randomized Clinical Trial

Cancer

 

Additional Info

Cancer
Impact of Adjuvant Trastuzumab on Locoregional Failure Rates in a Randomized Clinical Trial: North Central Cancer Treatment Group N9831 (Alliance) Study
Cancer 2020 Sep 15;[EPub Ahead of Print], CE Vargas, CS Thorpe, AC Dueck, KS Tenner, NE Davidson, S Martino, TM Pisansky, ES Hwang, MY Halyard, BA Pockaj, EA Perez

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading